Searched for
IMMUNO ONCOLOGY
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Zydus Lifesciences launches world's first nivolumab biosimilar in India, boosting cancer treatment affordabilityAhmedabad-based Zydus Lifesciences has launched Tishtha, the world's first biosimilar of the oncology drug nivolumab, in India. This move s...
- Zydus launches biosimilar for treatment of multiple cancersZydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha wi...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...
- Zydus to acquire US biotech firm Agenus’ facilities in CaliforniaZydus Lifesciences is set to acquire Agenus Inc.'s biologics manufacturing facilities in California for $75 million upfront and $50 million...
- Dr Reddy's launches novel cancer therapy Toripalimab in IndiaDr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma ...
- Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinomaDr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (N...
- Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patientsThe Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...
- Bugworks Research bags $18 million in funding round led by Lightrock India, othersBugworks Research said it will continue to invest in its proprietary drug discovery platforms GYROX (for AMR) and DARE (for Immuno-oncology...
- Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 milli...
- Zumutor Biologics gets $4 million in fresh fundsThe company said the capital will be used for the process of new drug filing of its lead molecule (ZM 008) in India, and to go through the ...
- Glenmark, APC Therapeutics ink licensing pact for cancer drugUnder the terms of the agreement, Glenmark will license the product from APC Therapeutics and manage all clinical development, including re...
- Glenmark anti-myeloma drug gets clinical trial nod from USFDAThis is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.
- Jubilant Life signs $180 mn outlicensing deal with Checkpoint"The pact includes an upfront payment of $2 mn and contingent pre-clinical, clinical and regulatory payments including commercials up to $1...
- Boehringer Ingelheim not for immuno therapy drugsA patient of a recently introduced immuno therapy drug is former US President Jimmy Carter who was treated with the drug Keytruda of Merck ...
- Global pharma growth to remain steady despite cost pressures: Moody'sCompanies like Bristol Myers Squibb, Merck &Co who have launched the new class cancer drugs in the area of immuno-oncology are expected to ...
- Merck KGaA bets on cancer drugs to revitalise German firmMerck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, ...
- DRL's Aurigene ties up with US firm CurisCuris has agreed to make payments of up to $52.5 million per programme including $42.5 million for approval and commercial milestones,
Load More
